Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 166

The DOI matches its Crossref record.

The prognostic value of GLUT1 in cancers: a systematic review and meta-analysis

Open access
Yu, Min, Yongzhi, Han, Chen, Shengying, Luo, Xiaodan, Lin, Ye, Zhou, Yu, Jin, Haosheng, Hou, Baohua, Deng, Yanying, Tu, Lei, Jian, Zhixiang·2017·Oncotarget

Abstract

// Min Yu 1, * , Han Yongzhi 2, * , Shengying Chen 1, * , Xiaodan Luo 3 , Ye Lin 1 , Yu Zhou 1 , Haosheng Jin 1 , Baohua Hou 1 , Yanying Deng 1 , Lei Tu 1 and Zhixiang Jian 1 1 Department of General Surgery, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China 2 Department of Dermatology, Guangdong General Hospital, Guangdong Academy of Medical Science, Guangzhou, China 3 Department of Infectious Diseases, Guangdong General Hospital, Guangdong Academy of Medical Science, Guangzhou, China * These authors contributed equally to this work Correspondence to: Min Yu, email: yuminzhongda@163.com Keywords: glucose transporter 1, prognostic marker, survival, cancer, glycolysis Received: July 18, 2016 Accepted: April 06, 2017 Published: April 27, 2017 ABSTRACT Increased glycolysis is one of the hallmarks of cancer. The abnormal expression of glucose transporter 1 (GLUT1) was reported to be associated with resistance to current therapy and poor prognosis. Numerous studies have investigated the correlation between GLUT1 expression and prognosis in cancers, but the conclusions are still controversial. Here, we conducted a meta-analysis to explore the association between GLUT1 and survival in human cancers. PubMed, Springer, Medline, and Cochrane Library were searched carefully to identify eligible studies evaluating prognostic value of GLUT1 in cancers. Twenty-seven studies with 4079 patients were included in the present study. Our pooled results identified that increased expression of GLUT1 was associated with unfavorable overall survival (HR = 1.780, 95% CI = 1.574–.013, p < 0.001)) and poorer disease-free survival (HR = 1.95, 95% CI = 1.229–3.095, p = 0.003). Furthermore, overexpression of GLUT1 linked with poor differentiated tumors (RR = 1.380, 95% CI = 1.086–1.755, p = 0.009; I 2 = 72.0%, p < 0.001), positive lymph node metastasis (RR = 1.395, 95% CI = 1.082–1.799, p = 0.010; I 2 = 70.8%, p = 0.002) and larger tumor size (RR = 1.405, 95% CI = 1.231–1.603, p < 0.001; I 2 = 37.3%, p = 0.093). This systematic review and meta-analysis indicated that the GLUT1 may serve as an ideal prognostic biomarker in various cancers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.17445

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 166

Metadata

Authors
Yu, M., Yongzhi, H., Chen, S., Luo, X., Lin, Y., Zhou, Y., Jin, H., Hou, B., Deng, Y., Tu, L., & Jian, Z.
Venue
Oncotarget
Published
2017-04-27
Volume
8
Issue
26
Pages
43356-43367
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2607721315
Cited by
166
References
0
FWCI
1.35
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The prognostic value of GLUT1 in cancers: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.18632/oncotarget.17445
The paper
Yu, M., Yongzhi, H., Chen, S., Luo, X., Lin, Y., Zhou, Y., Jin, H., Hou, B., Deng, Y., Tu, L., & Jian, Z. (2017). The prognostic value of GLUT1 in cancers: a systematic review and meta-analysis. Oncotarget. https://doi.org/10.18632/oncotarget.17445

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.